Athersys

About that Athersys stem cell stroke clinic trial PR…

Athersys

There has been a lot of excitement this week about a press release from stem cell biotech Athersys that reported that treatment of stroke patients with its product MultiStem was associated with a statistically significant improvement at 1-year. This sounds encouraging and the stock has spiked up as a result. However, there are some naysayers …

About that Athersys stem cell stroke clinic trial PR… Read More »

Key questions for stem cell field bouncing around on a Friday morning

ViaCyte-New-Logo

What are the most interesting questions for the stem cell field in 2014 right now? What’s on your mind? I’m not going to give this deep thought, but rather just list those questions bouncing around at the moment in no particular order. You can see a lot of translational/clinical things are on my mind. I’ve …

Key questions for stem cell field bouncing around on a Friday morning Read More »

Mesoblast (MSB) buys Osiris (OSIR) stem cell unit

The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal, …

Mesoblast (MSB) buys Osiris (OSIR) stem cell unit Read More »

My response to ‘Our Bodies, Our Cells’ Harvard post on deregulation

Mary-Ann-Chirba

Over at the Harvard Law “Bill of Health” blog, Mary Ann Chirba and Alice A. Nobel posted a piece entitled “Our Bodies, Our Cells” a few days ago that has generated a lot of discussion about FDA regulation of stem cell interventions. Their piece really has two parts. In the first part they go through …

My response to ‘Our Bodies, Our Cells’ Harvard post on deregulation Read More »